India presently serves to nearly 50% of the world's demand for pharmaceutical products, princely part of which are based on the usage of biotechnological applications. Currently, biopharmaceuticals are one among the fastest-growing biotechnology segments in India. The significant biopharmaceutical clusters of India are located in Haridwar, Sikkim, Hyderabad, Vishakhapatnam, Chennai, Pondicherry, Mysore, Mumbai, Ahmedabad, and Delhi NCR.

Government initiatives and investments:
The major investors within the Indian bio-pharmaceutical market are AstraZeneca, Johnson & Johnson, GlaxoSmithKline (GSK), Nipro and Otsuka. In 2017, 46 mergers and acquisition (M&A) deals were signed within the Indian biopharmaceutical market, generating business worth INR 94.77 Bn. The Indian government has taken the initiative to line up an electronic platform for regulating online pharmacies. Pharma Vision 2020' has been unveiled in order that India can emerge as a worldwide leader in terms of end-to-end drug manufacturing.

Key growth drivers of the market:
India comprises of ~0.13 Mn highly skilled and experienced scientists who function a robust network for the business process of the biopharmaceutical industry. With the assistance of the tutorial qualifications and skillset of those people, India is taken into account to be a big centre for biopharmaceutical research and development (R&D), especially for vaccine manufacturing. The Government of India has approved an investment of INR 15,000 Mn under the Innovate in India (i3) program, for collaboration of commercial organizations and academic organizations over subsequent five years. This program is taken into account to act as a big action of the govt in its way of boosting bio-pharmaceutical production within the country.

Key deterrents to the growth of the market:
It often takes an extended time for the manufacturing companies to launch a replacement market-ready bio-pharmaceutical product in India thanks to the existence of various regulatory challenges within the process.
Also, the Indian biopharmaceutical industry lacks proper infrastructure regarding limited government-sponsored laboratory space, consumables, chemical components, and equipment, which acts as a big hindrance to the expansion of the market.